| CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis A Laine, SG Nagelli, C Farrington, U Butt, AN Cvrljevic, JP Vainonen, ... Cancer research 81 (16), 4319-4331, 2021 | 32 | 2021 |
| Targeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI/ADR-RES cells in a 3D spheroid model BS Pattni, SG Nagelli, B Aryasomayajula, PP Deshpande, A Kulkarni, ... Pharmaceutical research 33, 2540-2551, 2016 | 19 | 2016 |
| Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias E Mäkelä, K Pavic, T Varila, U Salmenniemi, E Löyttyniemi, SG Nagelli, ... Clinical Cancer Research 27 (10), 2848-2860, 2021 | 14 | 2021 |
| CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis A Laine, SG Nagelli, C Farrington, U Butt, AN Cvrljevic, JP Vainonen, ... bioRxiv, 2020.08. 27.269902, 2020 | 3 | 2020 |
| CIP2A as a novel target to combat basal like breast cancer S Nagelli, A Laine, T Suomi, L Elo, J Westermarck Annals of Oncology 30, iii14-iii15, 2019 | 3 | 2019 |
| CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response S Nagelli, J Westermarck Trends in Cancer, 2023 | 2 | 2023 |
| Updating cancer research with patient-focused networks M Valiente, E Ortega-Paino Trends in Cancer, 2023 | | 2023 |
| Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias E Mäkelä, K Pavic, T Varila, U Salmenniemi, E Löyttyniemi, S Nagelli, ... bioRxiv, 2020.08. 24.264606, 2020 | | 2020 |
| Abstract P6-10-28: Therapeutic stratification of triple negative breast cancer by integrating chemosensitivity & phospho-proteome profiles P Gautam, X Qin, J Vainonen, S Nagelli, J Lampe, J Klefström, ... Cancer Research 80 (4_Supplement), P6-10-28-P6-10-28, 2020 | | 2020 |
| Therapeutic stratification of triple negative breast cancer by integrating chemosensitivity & phosphoproteome profiles P Gautam, X Qin, J Vainonen, S Nagelli, J Lampe, J Klefstrom, ... CANCER RESEARCH 80 (4), 2020 | | 2020 |
| PO-300 CIP2A-mediated regulation of senescence in basal-like breast cancer A Laine, S Nagelli, E Peuhu, CS Hau, O Kauko, P Kronqvist, H Sihto, ... ESMO Open 3, A345, 2018 | | 2018 |
| Development of transferrin targeted NCL-240 micelles and their evaluation using in-vitro 3D cancer cell culture (spheroid) models SG Nagelli Northeastern University, 2014 | | 2014 |
| CIP2A IS A CRITICAL DNA DAMAGE RESPONSE PROTEIN THAT DRIVES BASAL-LIKE BREAST CANCER S Nagelli | | |
Abhijit KulkarniConsultant - Medical Science Liaison; Eli Lilly and CompanyVerified email at lilly.com
